# US 2022/0028483 A1 · Systems and methods for classifying tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0028483 A1
- Document ID: US20220028483A1
- Status: Published application
- Kind: A1
- Application number: 17/277,647
- Filed: 2019-09-18
- Published: 2022-01-27
- Earliest claimed: 2018-09-24
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Doga C. GULHAN; Peter J. PARK
- Web page: https://patentgrep.com/patent/US20220028483A1

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G06N 20/10: using kernel methods, e.g. support vector machines [SVM]
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G06N 5/01: Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
- G06N 20/20: Ensemble learning
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Disclosed are systems and methods that can identify mutational signatures relevant to various cancers and/or treatments using genetic data from the tumors. This includes using a likelihood based measure, to compare clusters of tumor spectrums when the sample has sequenced only a sub-set of the genes with a targeted panel. In one example, by enabling panel-based identification of mutational signatures, our method substantially increases the number of patients that may be considered for treatments targeting HR deficiency.

## Claims

### Claim 1

A method of classifying a tumor of a patient, the method comprising:
obtaining a sample of a patient's tumor tissue;
performing DNA sequencing on the sample to output a set of genetic data;
performing a mutation analysis on the set of genetic data to output a set of mutations;
determining a sample mutational spectrum based on the set of mutations;
comparing the mutational spectrum to a set of clusters comprising different mutational spectrums to determine a matching cluster; and
outputting an indication of a mutational signature of the sample based on the matching cluster.

### Claim 2 (depends on 1)

The method of claim 1, wherein comparing the set of clusters to determine a matching cluster further comprises:
performing a likelihood comparison to output a likelihood feature;
performing a cosine similarity measure to output a cosine similarity feature; and
inputting the likelihood feature and the cosine similarity feature into a gradient boosted machine trained for a specific tumor type using WSG data to output a matching score.

### Claim 3 (depends on 1)

The method of claim 1, wherein performing DNA sequencing on the sample a mutation comprises performing DNA sequencing on a subset of the genes of the sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein outputting an indication further comprises outputting a recommended treatment for the patient based on the mutational signature.

### Claim 5 (depends on 1)

The method of claim 1, wherein comparing comprises using a likelihood similarity measure.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tumor type comprises breast cancer, ovarian cancer, osteosarcoma, endometrial carcinoma, bladder cancer, medulloblastoma, prostate adenocarcinoma, Ewing's sarcoma, pancreatic adenocarcinoma, pancreatic neuroendocrine cancer, or esophageal adenocarcinoma.

### Claim 7 (depends on 1)

The method of claim 1, wherein the set of genetic data comprises the whole genome of the sample.

### Claim 8 (depends on 2)

The method of claim 2, wherein the subset of genes comprises between 50-20000 genes.

### Claim 9 (depends on 2)

The method of claim 2, wherein the subset of genes comprises between 300-700 genes.

### Claim 10 (depends on 2)

The method of claim 2, wherein the subset of genes comprises at least 300 genes.

### Claim 11 (depends on 2)

The method of claim 2, wherein the subset of genes comprises 410 genes.

### Claim 12 (depends on 1)

The method of claim 1, wherein the set of clusters are determined using WSG and based on which of 96 mutations are present in each sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein the set of clusters are determined using hierarchical clustering based on the fractional occurrence of each mutation in a sample.

### Claim 14 (depends on 1)

The method of claim 1, wherein the mutational spectrums comprise probability distributions.

### Claim 15

A method of classifying a tumor of a patient, the method comprising:
receiving a mutation analysis on a subset of genes on a sample of a patient's tumor tissue to output a set of mutations;
determining a sample mutational spectrum based on the set of mutations;
comparing the mutational spectrum to a set of clusters comprising different mutational spectrums to determine a matching cluster; and
determining a mutational signature of the sample based on the matching cluster; and
treating the patient based on the determined mutational signature.

### Claim 16 (depends on 15)

The method of claim 15, wherein treating the patient comprises treating the patient with a PARP inhibitor or Po1 theta inhibitor if the mutational signature relates to homologous recombination deficiency.

### Claim 17 (depends on 15)

The method of claim 15, wherein treating the patient comprises treating the patient with a treatment targeting homologous recombination deficiency if the mutational signature relates to homologous recombination deficiency.

### Claim 18 (depends on 15)

The method of claim 15, wherein mutational signature relates to a deficiency in the DNA repair pathway.

### Claim 19

A method of classifying a tumor of a patient, the method comprising:
receiving a gene analysis on a subset of genes on a sample of a patient's tumor tissue from to output a set of mutations;
determining a signature three mutation profile status based on the set of mutations; and
treating the patient with a PARP inhibitor based on the signature three mutation profile status.

### Claim 20 (depends on 19)

The method of claim 19, wherein the tumor comprises breast cancer, ovarian cancer, osteosarcoma, endometrial carcinoma, bladder cancer, medulloblastoma, prostate adenocarcinoma, Ewing's sarcoma, pancreatic adenocarcinoma, pancreatic neuroendocrine cancer, or esophageal adenocarcinoma.
